← Back to Search

Monoclonal Antibodies

SOK583A1 for Age-Related Macular Degeneration

Phase 3
Waitlist Available
Research Sponsored by Sandoz
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 31 days
Awards & highlights

Study Summary

This trial is testing an injection given at baseline to see how effective it is; it will last approximately 31 days.

Eligible Conditions
  • Age-Related Macular Degeneration

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~31 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 31 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Participants With Non-ocular Treatment Emergent Adverse Events
Number of Participants With Ocular Treatment Emergent Adverse Events

Side effects data

From 2022 Phase 3 trial • 36 Patients • NCT05282004
42%
Intraocular pressure increased
6%
Conjunctival haemorrhage
3%
COVID-19
3%
Cystitis
3%
Vitreous floaters
3%
Arthralgia
100%
80%
60%
40%
20%
0%
Study treatment Arm
SOK583A1 40 mg/mL

Trial Design

1Treatment groups
Experimental Treatment
Group I: SOK583A1Experimental Treatment1 Intervention
SOK583A1 will be provided in a vial kit, with 40 mg/mL of aflibercept solution for IVT injection (2 mg/0.05 mL)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
SOK583A1
2022
Completed Phase 3
~40

Find a Location

Who is running the clinical trial?

SandozLead Sponsor
142 Previous Clinical Trials
26,521 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit
2022. "Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05282004.
~12 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top